Skip to main content
Jiangsu Lianhuan Pharmaceutical Co.,Ltd. logo

Jiangsu Lianhuan Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 600513 ISIN · CNE000001DP6 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,567 across all filing types
Latest filing 2026-05-29 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600513

About Jiangsu Lianhuan Pharmaceutical Co.,Ltd.

http://www.lhpharma.com/

Jiangsu Lianhuan Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing, and distribution of pharmaceutical products. The company focuses on several therapeutic areas, including cardiovascular diseases, urology, dermatology, and endocrinology. Key products include Felodipine sustained-release tablets, Terazosin Hydrochloride, and Ebastine. Operating with multiple GMP-certified production lines, the firm integrates chemical raw material synthesis with finished dosage form production. It maintains a robust research and development infrastructure to advance its pipeline of generic and innovative medicines. The company serves diverse markets, emphasizing quality control and technological innovation in its manufacturing processes.

Recent filings

Filing Released Lang Actions
联环药业关于公司收到药品GMP符合性检查结果的公告
Regulatory Filings Classification · 90% confidence The document is a formal announcement by Jiangsu Lianhuan Pharmaceutical Co., Ltd. regarding the receipt of a GMP compliance inspection result from the provincial drug regulatory authority. It contains regulatory compliance details (inspection scope, timeframe, conclusion) rather than financial statements, management changes, dividend notices, or M&A activity. It falls under general regulatory announcements (miscellaneous compliance filings) and does not constitute a financial report or presentation. Therefore, it is classified as a Regulatory Filing (RNS).
2026-05-29 Chinese
北京中伦（成都）律师事务所关于江苏联环药业股份有限公司2025年年度股东会的法律意见书
Regulatory Filings Classification · 82% confidence The document is a legal opinion letter (“法律意见书”) issued by Zhong Lun law firm regarding the convening procedures, attendee qualifications, and vote results of Jiangsu Lianhuan’s 2025 annual shareholders’ meeting. It does not present financial statements, proxy materials, or an investor presentation, nor is it a pure vote‐result notice from the company. Rather, it is a lawyer’s attestation on the legality of the meeting process. Under the “Certification Rule,” such attestation letters belong in Regulatory Filings (RNS) rather than a substantive report category.
2026-05-28 Chinese
联环药业2025年年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 90% confidence The document is the announcement of the resolutions passed at the 2025 Annual General Meeting of Jiangsu Lianhuan Pharmaceuticals Co., Ltd. It provides detailed vote counts and percentages for each proposal and confirms the legal procedures and lawyer witness opinion. This matches the definition for Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-05-28 Chinese
联环药业关于2025年度暨2026年第一季度业绩说明会召开情况的公告
Call Transcript Classification · 85% confidence The document is a public announcement (“公告”) describing the company’s 2025 annual and 2026 Q1 performance briefing (业绩说明会) held via the SSE roadshow platform, and it includes the full Q&A session between management and investors. This aligns with a conference‐call/briefing transcript category rather than a simple earnings release or regulatory filing. Therefore, it falls under Call Transcript (CT).
2026-05-28 Chinese
联环药业关于独立董事任期届满辞职的公告
Board/Management Information Classification · 90% confidence The document is an official announcement by the company’s board regarding the resignation of an independent director upon term expiration. It details the director’s departure and impact on board composition, which falls under board/management changes. It is not a financial report, proxy, or voting result but a management-level personnel change.
2026-05-21 Chinese
联环药业关于召开2025年度暨2026年第一季度业绩说明会的公告
Investor Presentation Classification · 78% confidence The document is a notice from Jiangsu Lianhuan Pharma about convening a performance briefing session (“业绩说明会”) to discuss the 2025 annual and 2026 Q1 results via video/online interaction. It does not contain actual financial data or results but is announcing an upcoming investor presentation format, time, participants, and logistics. This aligns with an Investor Presentation announcement (IP).
2026-05-20 Chinese

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.